62 results
8-K
EX-99.1
PYXS
Pyxis Oncology Inc
14 May 24
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
7:55am
agreement during the quarter ended March 31, 2024.
Research and development expenses were $13.0 million for the quarter ended March 31, 2024, compared …
Royalty revenues
Sale of royalty rights
Total revenues
Costs and operating expenses:
Cost of revenues
Research and development
General
8-K
EX-99.1
PYXS
Pyxis Oncology Inc
27 Mar 24
Other Events
4:09pm
Apexigen for the Period Ended August 22, 2023
Transaction Adjustments
Pro Forma Combined
Operating expenses:
Research and development
General … on management’s estimates of the fair value as of the acquisition date.
Intangible assets, net includes both in-process research and development (“IPR&D
8-K
EX-99.1
we4rvi45 6n7h4wxynjs
21 Mar 24
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
7:44am
8-K
4b46mwgl2in9k
28 Nov 23
Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer
7:22am
8-K
EX-99.1
kgywg127t1 j4t2m
7 Nov 23
Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update
4:44pm
8-K/A
EX-99.1
joc79ifzwxndyrge
27 Oct 23
Index to Consolidated Financial Statements
4:34pm
8-K/A
EX-99.3
o7azfoj6n49b0r842
27 Oct 23
Index to Consolidated Financial Statements
4:34pm
8-K/A
EX-99.2
tamdxo3hhfzmsa
27 Oct 23
Index to Consolidated Financial Statements
4:34pm
CORRESP
eftc9 y08l
28 Aug 23
Correspondence with SEC
12:00am
8-K
EX-99.1
v56aqlc 63
23 Aug 23
Pyxis Oncology Successfully Completes Acquisition of Apexigen
8:47am
UPLOAD
wbuypvnm547qdh du
16 Aug 23
Letter from SEC
12:00am
425
1cijw9e6 7x9
11 Aug 23
Business combination disclosure
7:26am
8-K
EX-99.1
do241usu2st2myun
11 Aug 23
Pyxis Oncology Reports Financial Results for Second-Quarter 2023
7:25am
425
878j0xx85od3la
11 Aug 23
Business combination disclosure
6:35am